3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
21
Neoplasms
6
Neoplasm Metastasis
5
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Triple Negative Breast Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hereditary Sensory and Autonomic Neuropathies
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Breast Diseases
2
von Hippel-Lindau Disease
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors Refractory to Standard Therapy
1
Solid Tumor, Adult
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Rare Tumor
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasm, Residual
1
Melanoma
1
Medulloblastoma
1
Malignant Female Reproductive System Neoplasm
1
Lung Neoplasms
1
Interventions
Fulvestrant
4
trastuzumab deruxtecan
2
elacestrant
2
Vinorelbine
2
toripalimab
1
talazoparib
1
ribociclib
1
pyrotinib
1
palbociclib
1
olaparib
1
exemestane
1
eribulin
1
disitamab vedotin
1
dalpiciclib
1
apatinib
1
abemaciclib
1
Selective Estrogen Receptor Modulators
1
Ritonavir
1
Radiotherapy
1
RAD1901
1
Letrozole
1
Itraconazole
1
Injections
1
Gonadotropin-Releasing Hormone
1
Everolimus
1
Capecitabine
1
Aromatase Inhibitors
1
Anastrozole
1
Ado-Trastuzumab Emtansine
1
AZD9833
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Advanced Breast Cancer
×
palbociclib
×
Clear all
NCT06380751
2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3
Recruiting
500 enrolled